Pulmonary Disease Clinical Trials

354 recruitingLast updated: June 17, 2026

There are 354 actively recruiting pulmonary disease clinical trials across 66 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, London, United Kingdom, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Pulmonary Disease Trials at a Glance

354 actively recruiting trials for pulmonary disease are listed on ClinicalTrialsFinder across 6 cities in 66 countries. The largest study group is Not Applicable with 128 trials, with the heaviest enrollment activity in Beijing, London, and Philadelphia. Lead sponsors running pulmonary disease studies include AstraZeneca, China-Japan Friendship Hospital, and Riphah International University.

Browse pulmonary disease trials by phase

Treatments under study

About Pulmonary Disease Clinical Trials

Looking for clinical trials for Pulmonary Disease? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 354 trials

Recruiting
Not Applicable

Mindful-Breath for People With COPD

MindfulnessChronic Obstructive Pulmonary Disease (COPD)Pulmonary Rehabilitation
The University of Hong Kong60 enrolled1 locationNCT07195838
Recruiting

Study of Microbiological Diversity in Exhaled Air in COPD and Free of COPD

Chronic Obstructive Pulmonary Disease
Centre Hospitalier Intercommunal Creteil240 enrolled1 locationNCT05437198
Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Pulmonary Disease, Chronic Obstructive
AstraZeneca2,000 enrolled7 locationsNCT06712563
Recruiting

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Pulmonary DiseasePulmonary Hypertension
National Institutes of Health Clinical Center (CC)270 enrolled1 locationNCT01730092
Recruiting

Study of Lung Proteins in Patients With Pneumonia

Pulmonary DiseasePneumoniaLung Disease
National Institutes of Health Clinical Center (CC)750 enrolled1 locationNCT00077909
Recruiting

Innate Immunity in COPD

Chronic Obstructive Pulmonary Disease
University of Edinburgh189 enrolled2 locationsNCT05743582
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled213 locationsNCT07190222
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled215 locationsNCT07190209
Recruiting

Study That Will Evaluate the Brazilian Population With COPD.

COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca693 enrolled10 locationsNCT06780046
Recruiting
Phase 4

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease
Sanofi218 enrolled68 locationsNCT07053423
Recruiting

Breathlessness Perceptions Within Respiratory Diseases

Chronic Obstructive Pulmonary Disease (COPD)BronchiectasisAsthma (Diagnosis)+2 more
University Hospitals, Leicester75 enrolled1 locationNCT07648082
Recruiting

Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality

Chronic Obstructive Pulmonary Disease (COPD)Cardiovascular DiseaseType 2 Diabetes
Steno Diabetes Center Copenhagen194 enrolled1 locationNCT07641309
Recruiting
Phase 3

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

Chronic Obstructive Pulmonary DiseaseCOPD
AstraZeneca82 enrolled13 locationsNCT07566195
Recruiting

Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics

Respiratory (Chronic Obstructive Pulmonary Disease)
AstraZeneca1,000 enrolled2 locationsNCT07315958
Recruiting
Phase 2

A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants With Moderate - Severe COPD

COPD, Chronic Obstructive Pulmonary Disease
Windward Bio105 enrolled3 locationsNCT07646587
Recruiting
Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

COPD, Chronic Obstructive Pulmonary Disease
Haisco Pharmaceutical Group Co., Ltd.376 enrolled1 locationNCT07583849
Recruiting
Not Applicable

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

Chronic Obstructive Pulmonary DiseaseInterstitial Lung DiseaseHypoxemia
State University of New York at Buffalo24 enrolled1 locationNCT07512687
Recruiting
Phase 3

Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure

Chronic Obstructive Pulmonary Disease ExacerbationObstructive Sleep Apnea Exacerbation
Assistance Publique - Hôpitaux de Paris386 enrolled1 locationNCT07047092
Recruiting
Phase 2

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca987 enrolled366 locationsNCT07082738
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Reistone Biopharma Company Limited300 enrolled1 locationNCT07349524